APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia A Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hemophilia A Drug Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchHemophilia A Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia A Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia A Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia A Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hemophilia A Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hemophilia A Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hemophilia A Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hemophilia A Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hemophilia A Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hemophilia A Drug include Bayer AG, mAbxience SA, LFB SA, Immusoft Corp, Idogen AB, Green Cross Corp, Expression Therapeutics LLC, EpiVax Inc and Dimension Therapeutics Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hemophilia A Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemophilia A Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Hemophilia A Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemophilia A Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemophilia A Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hemophilia A Drug sales, projected growth trends, production technology, application and end-user industry.

Hemophilia A Drug Segment by Company

Bayer AG

mAbxience SA

LFB SA

Immusoft Corp

Idogen AB

Green Cross Corp

Expression Therapeutics LLC

EpiVax Inc

Dimension Therapeutics Inc

DBV Technologies SA

CSL Ltd

Chugai Pharmaceutical Co Ltd

Catalyst Biosciences Inc

Bioverativ Inc

BioMarin Pharmaceutical Inc

Hemophilia A Drug Segment by Type

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

CSL-689

Others

Hemophilia A Drug Segment by Application

Clinic

Hospital

ASCs

Hemophilia A Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia A Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia A Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia A Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hemophilia A Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia A Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemophilia A Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. ATXF-8117 Major Manufacturers Table 3. BAY-1093884 Major Manufacturers Table 4. BIVV-001 Major Manufacturers Table 5. BS-027125 Major Manufacturers Table 6. Concizumab Major Manufacturers Table 7. CSL-689 Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Hemophilia A Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. ASCs Major Manufacturers Table 13. Hemophilia A Drug Industry Trends Table 14. Hemophilia A Drug Industry Drivers Table 15. Hemophilia A Drug Industry Opportunities and Challenges Table 16. Hemophilia A Drug Industry Restraints Table 17. Global Hemophilia A Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Hemophilia A Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Hemophilia A Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Hemophilia A Drug Revenue Market Share by Region (2021-2026) Table 21. Global Hemophilia A Drug Revenue Market Share by Region (2027-2032) Table 22. Global Hemophilia A Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Hemophilia A Drug Sales by Region (2021-2026) & (k units) Table 24. Global Hemophilia A Drug Sales by Region (2027-2032) & (k units) Table 25. Global Hemophilia A Drug Sales Market Share by Region (2021-2026) Table 26. Global Hemophilia A Drug Sales Market Share by Region (2027-2032) Table 27. Global Hemophilia A Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Hemophilia A Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Hemophilia A Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Hemophilia A Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Hemophilia A Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Hemophilia A Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Hemophilia A Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Hemophilia A Drug Manufacturers, Product Type & Application Table 35. Global Hemophilia A Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Hemophilia A Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Hemophilia A Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Hemophilia A Drug Revenue Market Share by Type (2021-2026) Table 42. Global Hemophilia A Drug Revenue Market Share by Type (2027-2032) Table 43. Global Hemophilia A Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 45. Global Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 46. Global Hemophilia A Drug Sales Market Share by Type (2021-2026) Table 47. Global Hemophilia A Drug Sales Market Share by Type (2027-2032) Table 48. Global Hemophilia A Drug Price by Type (2021-2026) & (US$/unit) Table 49. Global Hemophilia A Drug Price by Type (2027-2032) & (US$/unit) Table 50. Global Hemophilia A Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Hemophilia A Drug Revenue Market Share by Application (2021-2026) Table 54. Global Hemophilia A Drug Revenue Market Share by Application (2027-2032) Table 55. Global Hemophilia A Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 57. Global Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 58. Global Hemophilia A Drug Sales Market Share by Application (2021-2026) Table 59. Global Hemophilia A Drug Sales Market Share by Application (2027-2032) Table 60. Global Hemophilia A Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Hemophilia A Drug Price by Application (2027-2032) & (US$/unit) Table 62. Bayer AG Company Information Table 63. Bayer AG Business Overview Table 64. Bayer AG Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Bayer AG Hemophilia A Drug Product Portfolio Table 66. Bayer AG Recent Development Table 67. mAbxience SA Company Information Table 68. mAbxience SA Business Overview Table 69. mAbxience SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. mAbxience SA Hemophilia A Drug Product Portfolio Table 71. mAbxience SA Recent Development Table 72. LFB SA Company Information Table 73. LFB SA Business Overview Table 74. LFB SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. LFB SA Hemophilia A Drug Product Portfolio Table 76. LFB SA Recent Development Table 77. Immusoft Corp Company Information Table 78. Immusoft Corp Business Overview Table 79. Immusoft Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Immusoft Corp Hemophilia A Drug Product Portfolio Table 81. Immusoft Corp Recent Development Table 82. Idogen AB Company Information Table 83. Idogen AB Business Overview Table 84. Idogen AB Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Idogen AB Hemophilia A Drug Product Portfolio Table 86. Idogen AB Recent Development Table 87. Green Cross Corp Company Information Table 88. Green Cross Corp Business Overview Table 89. Green Cross Corp Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Green Cross Corp Hemophilia A Drug Product Portfolio Table 91. Green Cross Corp Recent Development Table 92. Expression Therapeutics LLC Company Information Table 93. Expression Therapeutics LLC Business Overview Table 94. Expression Therapeutics LLC Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Expression Therapeutics LLC Hemophilia A Drug Product Portfolio Table 96. Expression Therapeutics LLC Recent Development Table 97. EpiVax Inc Company Information Table 98. EpiVax Inc Business Overview Table 99. EpiVax Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. EpiVax Inc Hemophilia A Drug Product Portfolio Table 101. EpiVax Inc Recent Development Table 102. Dimension Therapeutics Inc Company Information Table 103. Dimension Therapeutics Inc Business Overview Table 104. Dimension Therapeutics Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio Table 106. Dimension Therapeutics Inc Recent Development Table 107. DBV Technologies SA Company Information Table 108. DBV Technologies SA Business Overview Table 109. DBV Technologies SA Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. DBV Technologies SA Hemophilia A Drug Product Portfolio Table 111. DBV Technologies SA Recent Development Table 112. CSL Ltd Company Information Table 113. CSL Ltd Business Overview Table 114. CSL Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. CSL Ltd Hemophilia A Drug Product Portfolio Table 116. CSL Ltd Recent Development Table 117. Chugai Pharmaceutical Co Ltd Company Information Table 118. Chugai Pharmaceutical Co Ltd Business Overview Table 119. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio Table 121. Chugai Pharmaceutical Co Ltd Recent Development Table 122. Catalyst Biosciences Inc Company Information Table 123. Catalyst Biosciences Inc Business Overview Table 124. Catalyst Biosciences Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio Table 126. Catalyst Biosciences Inc Recent Development Table 127. Bioverativ Inc Company Information Table 128. Bioverativ Inc Business Overview Table 129. Bioverativ Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Bioverativ Inc Hemophilia A Drug Product Portfolio Table 131. Bioverativ Inc Recent Development Table 132. BioMarin Pharmaceutical Inc Company Information Table 133. BioMarin Pharmaceutical Inc Business Overview Table 134. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio Table 136. BioMarin Pharmaceutical Inc Recent Development Table 137. North America Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 140. North America Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 141. North America Hemophilia A Drug Sales Price by Type (2021-2026) & (US$/unit) Table 142. North America Hemophilia A Drug Sales Price by Type (2027-2032) & (US$/unit) Table 143. North America Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 144. North America Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 145. North America Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 146. North America Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 147. North America Hemophilia A Drug Sales Price by Application (2021-2026) & (US$/unit) Table 148. North America Hemophilia A Drug Sales Price by Application (2027-2032) & (US$/unit) Table 149. North America Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Hemophilia A Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 151. North America Hemophilia A Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 152. North America Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 153. North America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 154. North America Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 155. North America Hemophilia A Drug Sales Price by Country (2021-2026) & (US$/unit) Table 156. North America Hemophilia A Drug Sales Price by Country (2027-2032) & (US$/unit) Table 157. United States Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 158. Canada Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 159. Mexico Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 160. Europe Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 161. Europe Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 162. Europe Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 163. Europe Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 164. Europe Hemophilia A Drug Sales Price by Type (2021-2026) & (US$/unit) Table 165. Europe Hemophilia A Drug Sales Price by Type (2027-2032) & (US$/unit) Table 166. Europe Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 167. Europe Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 168. Europe Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 169. Europe Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 170. Europe Hemophilia A Drug Sales Price by Application (2021-2026) & (US$/unit) Table 171. Europe Hemophilia A Drug Sales Price by Application (2027-2032) & (US$/unit) Table 172. Europe Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. Europe Hemophilia A Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 174. Europe Hemophilia A Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 175. Europe Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 176. Europe Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 177. Europe Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 178. Europe Hemophilia A Drug Sales Price by Country (2021-2026) & (US$/unit) Table 179. Europe Hemophilia A Drug Sales Price by Country (2027-2032) & (US$/unit) Table 180. Germany Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 181. France Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 182. U.K. Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 183. Italy Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 184. Russia Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 185. Spain Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 186. Netherlands Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 187. Switzerland Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 188. Sweden Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 189. Poland Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 190. China Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 191. China Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 192. China Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 193. China Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 194. China Hemophilia A Drug Sales Price by Type (2021-2026) & (US$/unit) Table 195. China Hemophilia A Drug Sales Price by Type (2027-2032) & (US$/unit) Table 196. China Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 197. China Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 198. China Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 199. China Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 200. China Hemophilia A Drug Sales Price by Application (2021-2026) & (US$/unit) Table 201. China Hemophilia A Drug Sales Price by Application (2027-2032) & (US$/unit) Table 202. Asia Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 203. Asia Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 204. Asia Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 205. Asia Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 206. Asia Hemophilia A Drug Sales Price by Type (2021-2026) & (US$/unit) Table 207. Asia Hemophilia A Drug Sales Price by Type (2027-2032) & (US$/unit) Table 208. Asia Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 209. Asia Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 210. Asia Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 211. Asia Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 212. Asia Hemophilia A Drug Sales Price by Application (2021-2026) & (US$/unit) Table 213. Asia Hemophilia A Drug Sales Price by Application (2027-2032) & (US$/unit) Table 214. Asia Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. Asia Hemophilia A Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. Asia Hemophilia A Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. Asia Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 218. Asia Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 219. Asia Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 220. Asia Hemophilia A Drug Sales Price by Country (2021-2026) & (US$/unit) Table 221. Asia Hemophilia A Drug Sales Price by Country (2027-2032) & (US$/unit) Table 222. Japan Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 223. South Korea Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 224. India Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 225. Australia Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 226. Taiwan Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 227. Southeast Asia Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 228. SAMEA Hemophilia A Drug Revenue by Type (2021-2026) & (US$ Million) Table 229. SAMEA Hemophilia A Drug Revenue by Type (2027-2032) & (US$ Million) Table 230. SAMEA Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 231. SAMEA Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 232. SAMEA Hemophilia A Drug Sales Price by Type (2021-2026) & (US$/unit) Table 233. SAMEA Hemophilia A Drug Sales Price by Type (2027-2032) & (US$/unit) Table 234. SAMEA Hemophilia A Drug Revenue by Application (2021-2026) & (US$ Million) Table 235. SAMEA Hemophilia A Drug Revenue by Application (2027-2032) & (US$ Million) Table 236. SAMEA Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 237. SAMEA Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 238. SAMEA Hemophilia A Drug Sales Price by Application (2021-2026) & (US$/unit) Table 239. SAMEA Hemophilia A Drug Sales Price by Application (2027-2032) & (US$/unit) Table 240. SAMEA Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 241. SAMEA Hemophilia A Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 242. SAMEA Hemophilia A Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 243. SAMEA Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 244. SAMEA Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 245. SAMEA Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 246. SAMEA Hemophilia A Drug Sales Price by Country (2021-2026) & (US$/unit) Table 247. SAMEA Hemophilia A Drug Sales Price by Country (2027-2032) & (US$/unit) Table 248. Brazil Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 249. Argentina Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 250. Chile Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 251. Colombia Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 252. Peru Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 253. Saudi Arabia Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 254. Israel Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 255. UAE Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 256. Turkey Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 257. Iran Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 258. Egypt Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Table 259. Key Raw Materials Table 260. Raw Materials Key Suppliers Table 261. Hemophilia A Drug Distributors List Table 262. Hemophilia A Drug Customers List Table 263. Research Programs/Design for This Report Table 264. Authors List of This Report Table 265. Secondary Sources Table 266. Primary Sources List of Figures Figure 1. Hemophilia A Drug Image Figure 2. Global Hemophilia A Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia A Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. ATXF-8117 Image Figure 5. BAY-1093884 Image Figure 6. BIVV-001 Image Figure 7. BS-027125 Image Figure 8. Concizumab Image Figure 9. CSL-689 Image Figure 10. Others Image Figure 11. Global Hemophilia A Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hemophilia A Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. ASCs Image Figure 16. Global Hemophilia A Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Hemophilia A Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Hemophilia A Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Hemophilia A Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Hemophilia A Drug Sales (2021-2032) & (k units) Figure 22. Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Hemophilia A Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Hemophilia A Drug Sales YoY (2021-2032) & (k units) Figure 25. Europe Hemophilia A Drug Sales YoY (2021-2032) & (k units) Figure 26. China Hemophilia A Drug Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Hemophilia A Drug Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Hemophilia A Drug Sales YoY (2021-2032) & (k units) Figure 29. Global Hemophilia A Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Hemophilia A Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Hemophilia A Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Hemophilia A Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Hemophilia A Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Hemophilia A Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Hemophilia A Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Hemophilia A Drug Sales Market Share by Type (2021-2032) Figure 38. Global Hemophilia A Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Hemophilia A Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Hemophilia A Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Hemophilia A Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Hemophilia A Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Hemophilia A Drug Sales Market Share by Application (2021-2032) Figure 44. North America Hemophilia A Drug Revenue Share by Type (2021-2032) Figure 45. North America Hemophilia A Drug Sales Share by Type (2021-2032) Figure 46. North America Hemophilia A Drug Revenue Share by Application (2021-2032) Figure 47. North America Hemophilia A Drug Sales Share by Application (2021-2032) Figure 48. North America Hemophilia A Drug Revenue Share by Country (2021-2032) Figure 49. North America Hemophilia A Drug Sales Share by Country (2021-2032) Figure 50. Europe Hemophilia A Drug Revenue Share by Type (2021-2032) Figure 51. Europe Hemophilia A Drug Sales Share by Type (2021-2032) Figure 52. Europe Hemophilia A Drug Revenue Share by Application (2021-2032) Figure 53. Europe Hemophilia A Drug Sales Share by Application (2021-2032) Figure 54. Europe Hemophilia A Drug Revenue Share by Country (2021-2032) Figure 55. Europe Hemophilia A Drug Sales Share by Country (2021-2032) Figure 56. China Hemophilia A Drug Revenue Share by Type (2021-2032) Figure 57. China Hemophilia A Drug Sales Share by Type (2021-2032) Figure 58. China Hemophilia A Drug Revenue Share by Application (2021-2032) Figure 59. China Hemophilia A Drug Sales Share by Application (2021-2032) Figure 60. Asia Hemophilia A Drug Revenue Share by Type (2021-2032) Figure 61. Asia Hemophilia A Drug Sales Share by Type (2021-2032) Figure 62. Asia Hemophilia A Drug Revenue Share by Application (2021-2032) Figure 63. Asia Hemophilia A Drug Sales Share by Application (2021-2032) Figure 64. Asia Hemophilia A Drug Revenue Share by Country (2021-2032) Figure 65. Asia Hemophilia A Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Hemophilia A Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Hemophilia A Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Hemophilia A Drug Revenue Share by Application (2021-2032) Figure 69. SAMEA Hemophilia A Drug Sales Share by Application (2021-2032) Figure 70. SAMEA Hemophilia A Drug Revenue Share by Country (2021-2032) Figure 71. SAMEA Hemophilia A Drug Sales Share by Country (2021-2032) Figure 72. Hemophilia A Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Hemophilia A Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • ATXF-8117
  • BAY-1093884
  • BIVV-001
  • BS-027125
  • Concizumab
  • CSL-689
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
Companies covered
  • Bayer AG
  • mAbxience SA
  • LFB SA
  • Immusoft Corp
  • Idogen AB
  • Green Cross Corp
  • Expression Therapeutics LLC
  • EpiVax Inc
  • Dimension Therapeutics Inc
  • DBV Technologies SA
  • CSL Ltd
  • Chugai Pharmaceutical Co Ltd
  • Catalyst Biosciences Inc
  • Bioverativ Inc
  • BioMarin Pharmaceutical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemophilia A Drug Market by Type
  3. 1.2.1 Global Hemophilia A Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 ATXF-8117
  5. 1.2.3 BAY-1093884
  6. 1.2.4 BIVV-001
  7. 1.2.5 BS-027125
  8. 1.2.6 Concizumab
  9. 1.2.7 CSL-689
  10. 1.2.8 Others
  11. 1.3 Hemophilia A Drug Market by Application
  12. 1.3.1 Global Hemophilia A Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 ASCs
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Hemophilia A Drug Market Dynamics
  1. 2.1 Hemophilia A Drug Industry Trends
  2. 2.2 Hemophilia A Drug Industry Drivers
  3. 2.3 Hemophilia A Drug Industry Opportunities and Challenges
  4. 2.4 Hemophilia A Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hemophilia A Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hemophilia A Drug Revenue by Region
  3. 3.2.1 Global Hemophilia A Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemophilia A Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Hemophilia A Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Hemophilia A Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hemophilia A Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hemophilia A Drug Sales by Region
  9. 3.4.1 Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hemophilia A Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Hemophilia A Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Hemophilia A Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hemophilia A Drug Revenue by Manufacturers
  2. 4.1.1 Global Hemophilia A Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hemophilia A Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hemophilia A Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemophilia A Drug Sales by Manufacturers
  6. 4.2.1 Global Hemophilia A Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hemophilia A Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hemophilia A Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hemophilia A Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hemophilia A Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hemophilia A Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hemophilia A Drug Manufacturers, Product Type & Application
  13. 4.7 Global Hemophilia A Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hemophilia A Drug Market CR5 and HHI
  16. 4.8.2 2025 Hemophilia A Drug Tier 1, Tier 2, and Tier 3
5 Hemophilia A Drug Market by Type
  1. 5.1 Global Hemophilia A Drug Revenue by Type
  2. 5.1.1 Global Hemophilia A Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hemophilia A Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hemophilia A Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hemophilia A Drug Sales by Type
  6. 5.2.1 Global Hemophilia A Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hemophilia A Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Hemophilia A Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hemophilia A Drug Price by Type
6 Hemophilia A Drug Market by Application
  1. 6.1 Global Hemophilia A Drug Revenue by Application
  2. 6.1.1 Global Hemophilia A Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hemophilia A Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hemophilia A Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hemophilia A Drug Sales by Application
  6. 6.2.1 Global Hemophilia A Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hemophilia A Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Hemophilia A Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hemophilia A Drug Price by Application
7 Company Profiles
  1. 7.1 Bayer AG
  2. 7.1.1 Bayer AG Company Information
  3. 7.1.2 Bayer AG Business Overview
  4. 7.1.3 Bayer AG Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Bayer AG Hemophilia A Drug Product Portfolio
  6. 7.1.5 Bayer AG Recent Developments
  7. 7.2 mAbxience SA
  8. 7.2.1 mAbxience SA Company Information
  9. 7.2.2 mAbxience SA Business Overview
  10. 7.2.3 mAbxience SA Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 mAbxience SA Hemophilia A Drug Product Portfolio
  12. 7.2.5 mAbxience SA Recent Developments
  13. 7.3 LFB SA
  14. 7.3.1 LFB SA Company Information
  15. 7.3.2 LFB SA Business Overview
  16. 7.3.3 LFB SA Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 LFB SA Hemophilia A Drug Product Portfolio
  18. 7.3.5 LFB SA Recent Developments
  19. 7.4 Immusoft Corp
  20. 7.4.1 Immusoft Corp Company Information
  21. 7.4.2 Immusoft Corp Business Overview
  22. 7.4.3 Immusoft Corp Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Immusoft Corp Hemophilia A Drug Product Portfolio
  24. 7.4.5 Immusoft Corp Recent Developments
  25. 7.5 Idogen AB
  26. 7.5.1 Idogen AB Company Information
  27. 7.5.2 Idogen AB Business Overview
  28. 7.5.3 Idogen AB Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Idogen AB Hemophilia A Drug Product Portfolio
  30. 7.5.5 Idogen AB Recent Developments
  31. 7.6 Green Cross Corp
  32. 7.6.1 Green Cross Corp Company Information
  33. 7.6.2 Green Cross Corp Business Overview
  34. 7.6.3 Green Cross Corp Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Green Cross Corp Hemophilia A Drug Product Portfolio
  36. 7.6.5 Green Cross Corp Recent Developments
  37. 7.7 Expression Therapeutics LLC
  38. 7.7.1 Expression Therapeutics LLC Company Information
  39. 7.7.2 Expression Therapeutics LLC Business Overview
  40. 7.7.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
  42. 7.7.5 Expression Therapeutics LLC Recent Developments
  43. 7.8 EpiVax Inc
  44. 7.8.1 EpiVax Inc Company Information
  45. 7.8.2 EpiVax Inc Business Overview
  46. 7.8.3 EpiVax Inc Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 EpiVax Inc Hemophilia A Drug Product Portfolio
  48. 7.8.5 EpiVax Inc Recent Developments
  49. 7.9 Dimension Therapeutics Inc
  50. 7.9.1 Dimension Therapeutics Inc Company Information
  51. 7.9.2 Dimension Therapeutics Inc Business Overview
  52. 7.9.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
  54. 7.9.5 Dimension Therapeutics Inc Recent Developments
  55. 7.10 DBV Technologies SA
  56. 7.10.1 DBV Technologies SA Company Information
  57. 7.10.2 DBV Technologies SA Business Overview
  58. 7.10.3 DBV Technologies SA Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
  60. 7.10.5 DBV Technologies SA Recent Developments
  61. 7.11 CSL Ltd
  62. 7.11.1 CSL Ltd Company Information
  63. 7.11.2 CSL Ltd Business Overview
  64. 7.11.3 CSL Ltd Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 CSL Ltd Hemophilia A Drug Product Portfolio
  66. 7.11.5 CSL Ltd Recent Developments
  67. 7.12 Chugai Pharmaceutical Co Ltd
  68. 7.12.1 Chugai Pharmaceutical Co Ltd Company Information
  69. 7.12.2 Chugai Pharmaceutical Co Ltd Business Overview
  70. 7.12.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
  72. 7.12.5 Chugai Pharmaceutical Co Ltd Recent Developments
  73. 7.13 Catalyst Biosciences Inc
  74. 7.13.1 Catalyst Biosciences Inc Company Information
  75. 7.13.2 Catalyst Biosciences Inc Business Overview
  76. 7.13.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
  78. 7.13.5 Catalyst Biosciences Inc Recent Developments
  79. 7.14 Bioverativ Inc
  80. 7.14.1 Bioverativ Inc Company Information
  81. 7.14.2 Bioverativ Inc Business Overview
  82. 7.14.3 Bioverativ Inc Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
  84. 7.14.5 Bioverativ Inc Recent Developments
  85. 7.15 BioMarin Pharmaceutical Inc
  86. 7.15.1 BioMarin Pharmaceutical Inc Company Information
  87. 7.15.2 BioMarin Pharmaceutical Inc Business Overview
  88. 7.15.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
  90. 7.15.5 BioMarin Pharmaceutical Inc Recent Developments
8 North America
  1. 8.1 North America Hemophilia A Drug Market Size by Type
  2. 8.1.1 North America Hemophilia A Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Hemophilia A Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Hemophilia A Drug Price by Type (2021-2032)
  5. 8.2 North America Hemophilia A Drug Market Size by Application
  6. 8.2.1 North America Hemophilia A Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Hemophilia A Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Hemophilia A Drug Price by Application (2021-2032)
  9. 8.3 North America Hemophilia A Drug Market Size by Country
  10. 8.3.1 North America Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hemophilia A Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Hemophilia A Drug Market Size by Type
  2. 9.1.1 Europe Hemophilia A Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hemophilia A Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Hemophilia A Drug Price by Type (2021-2032)
  5. 9.2 Europe Hemophilia A Drug Market Size by Application
  6. 9.2.1 Europe Hemophilia A Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hemophilia A Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Hemophilia A Drug Price by Application (2021-2032)
  9. 9.3 Europe Hemophilia A Drug Market Size by Country
  10. 9.3.1 Europe Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hemophilia A Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Hemophilia A Drug Market Size by Type
  2. 10.1.1 China Hemophilia A Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Hemophilia A Drug Sales by Type (2021-2032)
  4. 10.1.3 China Hemophilia A Drug Price by Type (2021-2032)
  5. 10.2 China Hemophilia A Drug Market Size by Application
  6. 10.2.1 China Hemophilia A Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Hemophilia A Drug Sales by Application (2021-2032)
  8. 10.2.3 China Hemophilia A Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemophilia A Drug Market Size by Type
  2. 11.1.1 Asia Hemophilia A Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hemophilia A Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Hemophilia A Drug Price by Type (2021-2032)
  5. 11.2 Asia Hemophilia A Drug Market Size by Application
  6. 11.2.1 Asia Hemophilia A Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hemophilia A Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Hemophilia A Drug Price by Application (2021-2032)
  9. 11.3 Asia Hemophilia A Drug Market Size by Country
  10. 11.3.1 Asia Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hemophilia A Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemophilia A Drug Market Size by Type
  2. 12.1.1 SAMEA Hemophilia A Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hemophilia A Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hemophilia A Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Hemophilia A Drug Market Size by Application
  6. 12.2.1 SAMEA Hemophilia A Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hemophilia A Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hemophilia A Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Hemophilia A Drug Market Size by Country
  10. 12.3.1 SAMEA Hemophilia A Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hemophilia A Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hemophilia A Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hemophilia A Drug Value Chain Analysis
  2. 13.1.1 Hemophilia A Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hemophilia A Drug Production Mode & Process
  6. 13.2 Hemophilia A Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hemophilia A Drug Distributors
  9. 13.2.3 Hemophilia A Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst